Albireo to participate in the h.c. wainwright global investment conference 2022

Boston, may 19, 2022 (globe newswire) -- albireo pharma, inc. (nasdaq: albo), a rare liver disease company developing novel bile acid modulators, today announced participation in the h.c. wainwright global life science conference may 23-26, 2022. simon harford, chief financial officer, will be presenting on wednesday, may 25, which will be available on-demand on the albireo investors page ir.albireopharma.com. simon and pamela stephenson, chief commercial officer, will host meetings with investors.
ALBO Ratings Summary
ALBO Quant Ranking